.Nature Medicine, Published online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec acquired FDA authorization after an adverse trial, which highlights the numerous difficulties as well as problems of drug progression in this environment.